LILIAN SERPAS: Open Payments
NPI 1396375390 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,516 in 148 payments from 17 companies in 2025. Trend: 2023 $1,654 · 2024 $3,486 · 2025 $4,516
Food & beverage: $4,246Education: $260Travel & lodging: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $880 |
| UCB, Inc. | 38 | $848 |
| Novartis Pharmaceuticals Corporation | 17 | $408 |
| Galderma Laboratories, L.P. | 12 | $398 |
| Incyte Corporation | 11 | $344 |
| Arcutis Biotherapeutics, Inc. | 14 | $252 |
| Organon LLC | 11 | $238 |
| GENZYME CORPORATION | 7 | $195 |
| Botanix SB Inc | 2 | $174 |
| LEO Pharma Inc. | 3 | $167 |
Products named: Bimzelx, SKYRIZI, DUPIXENT, NEMLUVIO, OPZELURA, Zoryve, VTAMA, RINVOQ.
Industry payments across CA — which companies pay providers there.
